{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:51:28Z","timestamp":1792547488320,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02941-9","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T03:00:38Z","timestamp":1753326038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epigenetic reprogramming of mast and cancer cells modifies tumor-promoting cytokine networks"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7734-3253","authenticated-orcid":false,"given":"Alejandro","family":"Schcolnik-Cabrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Ram\u00edrez-Yautentzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1884-8950","authenticated-orcid":false,"given":"Rodolfo","family":"Soria-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rommel","family":"Chac\u00f3n-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0963-4021","authenticated-orcid":false,"given":"Roc\u00edo","family":"Morales-B\u00e1rcenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-4493","authenticated-orcid":false,"given":"Guadalupe","family":"Dom\u00ednguez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Gonz\u00e1lez-Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2956-645X","authenticated-orcid":false,"given":"Alfonso","family":"Due\u00f1as-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-5935","authenticated-orcid":false,"given":"Alma","family":"Ch\u00e1vez-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"2941_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fimmu.2017.00424","volume":"8","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Marone G, et al. Are mast cells MASTers in cancer? Front Immunol. 2017;8:424. https:\/\/doi.org\/10.3389\/fimmu.2017.00424.","journal-title":"Front Immunol"},{"key":"2941_CR2","doi-asserted-by":"publisher","first-page":"09","DOI":"10.12703\/P7-09","volume":"7","author":"TT Maciel","year":"2015","unstructured":"Maciel TT, Moura IC, Hermine O. The role of mast cells in cancers. F1000Prime Rep. 2015;7:09. https:\/\/doi.org\/10.12703\/P7-09.","journal-title":"F1000Prime Rep."},{"issue":"3","key":"2941_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","volume":"58","author":"DEA Komi","year":"2020","unstructured":"Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313\u201325. https:\/\/doi.org\/10.1007\/s12016-019-08753-w.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2941_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.imlet.2019.03.011","volume":"209","author":"A Derakhshani","year":"2019","unstructured":"Derakhshani A, Vahidian F, Alihasanzadeh M, Mokhtarzadeh A, Lotfi Nezhad P, Baradaran B. Mast cells: a double-edged sword in cancer. Immunol Lett. 2019;209:28\u201335. https:\/\/doi.org\/10.1016\/j.imlet.2019.03.011.","journal-title":"Immunol Lett"},{"key":"2941_CR5","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.12688\/f1000research.12384.1","volume":"6","author":"S Monticelli","year":"2017","unstructured":"Monticelli S, Leoni C. Epigenetic and transcriptional control of mast cell responses. F1000Res. 2017;6:2064. https:\/\/doi.org\/10.12688\/f1000research.12384.1.","journal-title":"F1000Res"},{"key":"2941_CR6","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3389\/fphar.2019.00588","volume":"10","author":"S Patnaik","year":"2019","unstructured":"Patnaik S, Anupriya. Drugs targeting epigenetic modifications and plausible therapeutic strategies against colorectal cancer. Front Pharmacol. 2019;10:588. https:\/\/doi.org\/10.3389\/fphar.2019.00588.","journal-title":"Front Pharmacol"},{"key":"2941_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","volume":"58","author":"RL Bennett","year":"2018","unstructured":"Bennett RL, Licht JD. Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol. 2018;58:187\u2013207. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-105106.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2941_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4419-9967-2_1","volume":"754","author":"B Jin","year":"2013","unstructured":"Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3\u201329. https:\/\/doi.org\/10.1007\/978-1-4419-9967-2_1.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2941_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3892\/or.2019.7240","volume":"42","author":"G Dominguez-Gomez","year":"2019","unstructured":"Dominguez-Gomez G, Cortez-Pedroza D, Chavez-Blanco A, Taja-Chayeb L, Hidalgo-Miranda A, Cedro-Tanda A, et al. Growth inhibition and transcriptional effects of ribavirin in lymphoma. Oncol Rep. 2019;42(3):1248\u201356. https:\/\/doi.org\/10.3892\/or.2019.7240.","journal-title":"Oncol Rep"},{"key":"2941_CR10","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1038\/bcj.2014.14","volume":"4","author":"AO Gang","year":"2014","unstructured":"Gang AO, Frosig TM, Brimnes MK, Lyngaa R, Treppendahl MB, Gronbaek K, et al. 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J. 2014;4:e197. https:\/\/doi.org\/10.1038\/bcj.2014.14.","journal-title":"Blood Cancer J"},{"issue":"10","key":"2941_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1517\/17425255.2014.947263","volume":"10","author":"A Duenas-Gonzalez","year":"2014","unstructured":"Duenas-Gonzalez A, Coronel J, Cetina L, Gonzalez-Fierro A, Chavez-Blanco A, Taja-Chayeb L. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014;10(10):1433\u201344. https:\/\/doi.org\/10.1517\/17425255.2014.947263.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"2941_CR12","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3892\/ijo.2011.1144","volume":"39","author":"A Chavez-Blanco","year":"2011","unstructured":"Chavez-Blanco A, De la Cruz-Hernandez E, Dominguez GI, Rodriguez-Cortez O, Alatorre B, Perez-Cardenas E, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol. 2011;39(6):1491\u20139. https:\/\/doi.org\/10.3892\/ijo.2011.1144.","journal-title":"Int J Oncol"},{"issue":"2","key":"2941_CR13","first-page":"5","volume":"8","author":"A Schcolnik-Cabrera","year":"2018","unstructured":"Schcolnik-Cabrera A, Dominguez-Gomez G, Duenas-Gonzalez A. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells. Am J Blood Res. 2018;8(2):5\u201316.","journal-title":"Am J Blood Res"},{"issue":"3","key":"2941_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/JLB.3AB0320-547RR","volume":"108","author":"GM Rodriguez-Lopez","year":"2020","unstructured":"Rodriguez-Lopez GM, Soria-Castro R, Campillo-Navarro M, Perez-Tapia SM, Flores-Borja F, Wong-Baeza I, et al. The histone deacetylase inhibitor valproic acid attenuates phospholipase Cgamma2 and IgE-mediated mast cell activation. J Leukoc Biol. 2020;108(3):859\u201366. https:\/\/doi.org\/10.1002\/JLB.3AB0320-547RR.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2941_CR15","doi-asserted-by":"publisher","first-page":"15685","DOI":"10.1038\/s41598-022-20054-5","volume":"12","author":"R Soria-Castro","year":"2022","unstructured":"Soria-Castro R, Meneses-Preza YG, Rodriguez-Lopez GM, Ibarra-Sanchez A, Gonzalez-Espinosa C, Perez-Tapia SM, et al. Valproic acid restricts mast cell activation by Listeria monocytogenes. Sci Rep. 2022;12(1):15685. https:\/\/doi.org\/10.1038\/s41598-022-20054-5.","journal-title":"Sci Rep"},{"issue":"6","key":"2941_CR16","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.62347\/IDKG8587","volume":"14","author":"H Salamanca-Ortiz","year":"2024","unstructured":"Salamanca-Ortiz H, Dominguez-Gomez G, Chavez-Blanco A, Ortega-Bernal D, Diaz-Chavez J, Gonzalez-Fierro A, et al. The inhibitory and transcriptional effects of the epigenetic repurposed drugs hydralazine and valproate in lymphoma cells. Am J Cancer Res. 2024;14(6):3068\u201382. https:\/\/doi.org\/10.62347\/IDKG8587.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"2941_CR17","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.3892\/ol.2019.11008","volume":"18","author":"A Schcolnik-Cabrera","year":"2019","unstructured":"Schcolnik-Cabrera A, Dominguez-Gomez G, Chavez-Blanco A, Ramirez-Yautentzi M, Morales-Barcenas R, Chavez-Diaz J, et al. A combination of inhibitors of glycolysis, glutaminolysis and de novo fatty acid synthesis decrease the expression of chemokines in human colon cancer cells. Oncol Lett. 2019;18(6):6909\u201316. https:\/\/doi.org\/10.3892\/ol.2019.11008.","journal-title":"Oncol Lett"},{"issue":"1","key":"2941_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3892\/ijo.2012.1438","volume":"41","author":"K Yamanegi","year":"2012","unstructured":"Yamanegi K, Yamane J, Kobayashi K, Kato-Kogoe N, Ohyama H, Nakasho K, et al. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death. Int J Oncol. 2012;41(1):83\u201391. https:\/\/doi.org\/10.3892\/ijo.2012.1438.","journal-title":"Int J Oncol"},{"key":"2941_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2867-6-2","volume":"6","author":"A Chavez-Blanco","year":"2006","unstructured":"Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase INHIBITOR valproic acid in cancer cell lines. Cancer Cell Int. 2006;6:2. https:\/\/doi.org\/10.1186\/1475-2867-6-2.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"2941_CR20","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1182\/blood-2008-03-147033","volume":"112","author":"B Huang","year":"2008","unstructured":"Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008;112(4):1269\u201379. https:\/\/doi.org\/10.1182\/blood-2008-03-147033.","journal-title":"Blood"},{"issue":"8","key":"2941_CR21","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1158\/0008-5472.CAN-21-3424","volume":"82","author":"MT Majorini","year":"2022","unstructured":"Majorini MT, Colombo MP, Lecis D. Few, but efficient: the role of mast cells in breast cancer and other solid tumors. Cancer Res. 2022;82(8):1439\u201347. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3424.","journal-title":"Cancer Res"},{"key":"2941_CR22","doi-asserted-by":"publisher","first-page":"156596","DOI":"10.1016\/j.phymed.2025.156596","volume":"140","author":"L Gou","year":"2025","unstructured":"Gou L, Yue GG, Chan BC, Lau AH, Puno PT, Lau CB. Unveiling the role of mast cells in breast cancer-a case study of natural product Eriocalyxin B as an inhibitor. Phytomedicine. 2025;140:156596. https:\/\/doi.org\/10.1016\/j.phymed.2025.156596.","journal-title":"Phytomedicine"},{"issue":"4","key":"2941_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.prp.2009.10.005","volume":"206","author":"M Wilk","year":"2010","unstructured":"Wilk M, Liszka L, Palen P, Gabriel A, Laudanski P. Intensity of angiogenesis and mast cell infiltration in cervical intraepithelial and invasive lesions\u2014are they correlated? Pathol Res Pract. 2010;206(4):217\u201322. https:\/\/doi.org\/10.1016\/j.prp.2009.10.005.","journal-title":"Pathol Res Pract"},{"issue":"6","key":"2941_CR24","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/s0003-4975(00)01160-7","volume":"69","author":"M Tomita","year":"2000","unstructured":"Tomita M, Matsuzaki Y, Onitsuka T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg. 2000;69(6):1686\u201390. https:\/\/doi.org\/10.1016\/s0003-4975(00)01160-7.","journal-title":"Ann Thorac Surg"},{"issue":"9","key":"2941_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41419-024-07092-9","volume":"15","author":"R Bongiorno","year":"2024","unstructured":"Bongiorno R, Lecchi M, Botti L, Bosco O, Ratti C, Fontanella E, et al. Mast cell heparanase promotes breast cancer stem-like features via MUC1\/estrogen receptor axis. Cell Death Dis. 2024;15(9):709. https:\/\/doi.org\/10.1038\/s41419-024-07092-9.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2941_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12964-023-01110-7","volume":"21","author":"S Ben","year":"2023","unstructured":"Ben S, Huang X, Shi Y, Xu Z, Xiao H. Change in cytokine profiles released by mast cells mediated by lung cancer-derived exosome activation may contribute to cancer-associated coagulation disorders. Cell Commun Signal. 2023;21(1):97. https:\/\/doi.org\/10.1186\/s12964-023-01110-7.","journal-title":"Cell Commun Signal"},{"issue":"10","key":"2941_CR27","doi-asserted-by":"publisher","first-page":"e1004466","DOI":"10.1371\/journal.ppat.1004466","volume":"10","author":"AS Bergot","year":"2014","unstructured":"Bergot AS, Ford N, Leggatt GR, Wells JW, Frazer IH, Grimbaldeston MA. HPV16-E7 expression in squamous epithelium creates a local immune suppressive environment via CCL2- and CCL5- mediated recruitment of mast cells. PLoS Pathog. 2014;10(10):e1004466. https:\/\/doi.org\/10.1371\/journal.ppat.1004466.","journal-title":"PLoS Pathog"},{"issue":"5","key":"2941_CR28","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3892\/mmr.2014.2044","volume":"9","author":"C Aguilar","year":"2014","unstructured":"Aguilar C, Aguilar C, Lopez-Marure R, Jimenez-Sanchez A, Rocha-Zavaleta L. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1\/2. Mol Med Rep. 2014;9(5):1895\u2013902. https:\/\/doi.org\/10.3892\/mmr.2014.2044.","journal-title":"Mol Med Rep"},{"issue":"3","key":"2941_CR29","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.3892\/ol.2020.11838","volume":"20","author":"A Schcolnik-Cabrera","year":"2020","unstructured":"Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Juarez M, Lai D, Hua S, et al. The combination of orlistat, lonidamine and 6-diazo-5-oxo-L-norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells. Oncol Lett. 2020;20(3):3053\u201360. https:\/\/doi.org\/10.3892\/ol.2020.11838.","journal-title":"Oncol Lett"},{"issue":"1","key":"2941_CR30","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1038\/s41598-021-84538-6","volume":"11","author":"A Schcolnik-Cabrera","year":"2021","unstructured":"Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Juarez M, Vargas-Castillo A, Ponce-Toledo RI, et al. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. Sci Rep. 2021;11(1):5222. https:\/\/doi.org\/10.1038\/s41598-021-84538-6.","journal-title":"Sci Rep"},{"issue":"11","key":"2941_CR31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1097\/01.lab.0000036875.21209.f9","volume":"82","author":"I Esposito","year":"2002","unstructured":"Esposito I, Kleeff J, Bischoff SC, Fischer L, Collecchi P, Iorio M, et al. The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest. 2002;82(11):1481\u201392. https:\/\/doi.org\/10.1097\/01.lab.0000036875.21209.f9.","journal-title":"Lab Invest"},{"issue":"1","key":"2941_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13046-019-1118-y","volume":"38","author":"W Xu","year":"2019","unstructured":"Xu W, Qian J, Zeng F, Li S, Guo W, Chen L, et al. Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment. J Exp Clin Cancer Res. 2019;38(1):114. https:\/\/doi.org\/10.1186\/s13046-019-1118-y.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2941_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00005-023-00676-x","volume":"71","author":"D Ribatti","year":"2023","unstructured":"Ribatti D. Mast cells and resistance to immunotherapy in cancer. Arch Immunol Ther Exp (Warsz). 2023;71(1):11. https:\/\/doi.org\/10.1007\/s00005-023-00676-x.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"3","key":"2941_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.tranon.2014.03.001","volume":"7","author":"J Bauman","year":"2014","unstructured":"Bauman J, Shaheen M, Verschraegen CF, Belinsky SA, Houman Fekrazad M, Lee FC, et al. A phase I protocol of hydralazine and valproic acid in advanced, previously treated solid cancers. Transl Oncol. 2014;7(3):349\u201354. https:\/\/doi.org\/10.1016\/j.tranon.2014.03.001.","journal-title":"Transl Oncol"},{"issue":"1","key":"2941_CR35","doi-asserted-by":"publisher","first-page":"20271","DOI":"10.1038\/s41598-019-56854-5","volume":"9","author":"FO Andrade","year":"2019","unstructured":"Andrade FO, Nguyen NM, Warri A, Hilakivi-Clarke L. Reversal of increased mammary tumorigenesis by valproic acid and hydralazine in offspring of dams fed high fat diet during pregnancy. Sci Rep. 2019;9(1):20271. https:\/\/doi.org\/10.1038\/s41598-019-56854-5.","journal-title":"Sci Rep"},{"issue":"2","key":"2941_CR36","first-page":"140","volume":"35","author":"E Mani","year":"2014","unstructured":"Mani E, Medina LA, Isaac-Olive K, Duenas-Gonzalez A. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate. Eur J Gynaecol Oncol. 2014;35(2):140\u20132.","journal-title":"Eur J Gynaecol Oncol"},{"key":"2941_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155293","author":"A Aponte-Lopez","year":"2020","unstructured":"Aponte-Lopez A, Enciso J, Munoz-Cruz S, Fuentes-Panana EM. An in vitro model of mast cell recruitment and activation by breast cancer cells supports anti-tumoral responses. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21155293.","journal-title":"Int J Mol Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02941-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02941-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02941-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:46:23Z","timestamp":1756442783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02941-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2941"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02941-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"371"}}